Patents Assigned to Biosynexus Incorporated
-
Patent number: 8697639Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: GrantFiled: April 13, 2009Date of Patent: April 15, 2014Assignee: Biosynexus IncorporatedInventors: Scott M. Walsh, Mary C. Pittaway, James J. Mond
-
Patent number: 8568731Abstract: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising the polypeptides; recombinant methods to manufacture the polypeptides; and therapeutic antibodies directed to the polypeptides.Type: GrantFiled: September 8, 2009Date of Patent: October 29, 2013Assignee: Biosynexus IncorporatedInventors: Simon Foster, Philip McDowell, Kirsty Brummell, Simon Clarke
-
Patent number: 8372958Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.Type: GrantFiled: June 23, 2003Date of Patent: February 12, 2013Assignee: Biosynexus Incorporated;Inventors: Gerald W. Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
-
Publication number: 20110236399Abstract: This invention is directed to compositions and methods for treating (e.g., prophylactically and/or therapeutically) infection in a preterm infant. In particular, the invention provides anti-lipoteichoic acid (LTA) antibody compositions and methods of administering the same to a preterm infant (e.g., a low birth weight preterm infant (e.g., a very low birth weight preterm infant)) under conditions to establish anti-LTA antibody serum concentrations effective to kill and/or prevent growth of bacteria (e.g., Staphylococci). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications.Type: ApplicationFiled: March 29, 2011Publication date: September 29, 2011Applicant: BIOSYNEXUS INCORPORATEDInventors: James J. Mond, Irwin Scher, John F. Kokai-Kun
-
Publication number: 20100260752Abstract: This invention provides binding molecules with improved binding affinity to lipoteichoic acids exposed on the surface of the bacteria, useful in the prevention and treatment of infections caused by Gram positive bacteria.Type: ApplicationFiled: January 22, 2010Publication date: October 14, 2010Applicant: Biosynexus IncorporatedInventor: Ying TANG
-
Publication number: 20100221237Abstract: Methods for treating patients in which damaged tissue or an indwelling prosthetic device or catheter has a bacterial biofilm growing thereon, to at least partially disrupt said biofilm, by administering at least one antibacterial enzyme that is lethal or damaging to the biofilm-forming bacteria in an amount that is effective to at least partially disrupt the biofilm upon contact therewith. Methods for prophylactically treating a patient, and methods for disinfecting or sterilizing a surface ex-vivo to remove a biofilm or prevent biofilm growth are also disclosed, as well as implantable articles susceptible to biofilm growth to which a prophylactic coating of an antibacterial enzyme has been applied.Type: ApplicationFiled: August 10, 2009Publication date: September 2, 2010Applicant: BIOSYNEXUS INCORPORATEDInventors: John F. Kokai-Kun, Julie Adams Wu, James J. Mond, Scott M. Walsh, Anjali G. Shah, Tatyana I. Chanturiya
-
Patent number: 7777017Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: GrantFiled: March 13, 2007Date of Patent: August 17, 2010Assignee: Biosynexus IncorporatedInventors: Jeffrey R. Stinson, Richard F. Schuman, James Jacob Mond, Andrew Lees, Gerald Walter Fischer
-
Publication number: 20100166792Abstract: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides.Type: ApplicationFiled: September 8, 2009Publication date: July 1, 2010Applicant: BIOSYNEXUS INCORPORATEDInventors: Simon Foster, Philip McDowell, Kirsty Brummell, Simon Clarke
-
Publication number: 20090304783Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: ApplicationFiled: August 17, 2009Publication date: December 10, 2009Applicant: BIOSYNEXUS INCORPORATEDInventors: Scott Michael Walsh, Mary Catherine Pittaway, James J. Mond
-
Patent number: 7585658Abstract: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising such polypeptides; recombinant methods to manufacture such polypeptides; and therapeutic antibodies directed to such polypeptides.Type: GrantFiled: October 24, 2005Date of Patent: September 8, 2009Assignee: Biosynexus IncorporatedInventors: Simon Foster, Philip McDowell, Kirsty Brummell, Simon Clarke
-
Patent number: 7576054Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: GrantFiled: October 11, 2006Date of Patent: August 18, 2009Assignee: Biosynexus IncorporatedInventors: Scott Michael Walsh, Mary Catherine Pittaway, James J. Mond
-
Patent number: 7572439Abstract: Methods for treating patients in which damaged tissue or an indwelling prosthetic device or catheter has a bacterial biofilm growing thereon, to at least partially disrupt said biofilm, by administering at least one antibacterial enzyme that is lethal or damaging to the biofilm-forming bacteria in an amount that is effective to at least partially disrupt the biofilm upon contact therewith. Methods for prophylactically treating a patient, and methods for disinfecting or sterilizing a surface ex-vivo to remove a biofilm or prevent biofilm growth are also disclosed, as well as implantable articles susceptible to biofilm growth to which a prophylactic coating of an antibacterial enzyme has been applied.Type: GrantFiled: March 26, 2003Date of Patent: August 11, 2009Assignee: Biosynexus IncorporatedInventors: John F. Kokai-Kun, Julie M. Adams, James J. Mond, Scott M. Walsh, Anjali G. Shah, Tanya I. Chanturiya
-
Publication number: 20090196945Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: ApplicationFiled: April 13, 2009Publication date: August 6, 2009Applicant: BIOSYNEXUS INCORPORATEDInventors: Scott Michael Walsh, Mary Catherine Pittaway, James J. Mond
-
Patent number: 7517852Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: GrantFiled: July 28, 2006Date of Patent: April 14, 2009Assignee: Biosynexus IncorporatedInventors: Scott Michael Walsh, Mary Catherine Pittaway, James J. Mond
-
Publication number: 20090081180Abstract: Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.Type: ApplicationFiled: November 14, 2008Publication date: March 26, 2009Applicant: BIOSYNEXUS, INCORPORATEDInventors: Scott M. Walsh, Anjali G. Shah, James J. Mond, Andrew Lees, Joseph J. Drabick
-
Patent number: 7452533Abstract: Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.Type: GrantFiled: March 26, 2003Date of Patent: November 18, 2008Assignee: Biosynexus IncorporatedInventors: Scott M. Walsh, Anjali G. Shah, James J. Mond, Andrew Lees, Joseph J. Drabick
-
Patent number: 7410647Abstract: A method for the identification of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes; vaccines comprising said antigens; and therapeutic antibodies directed to said antigenic polypeptides.Type: GrantFiled: August 2, 2002Date of Patent: August 12, 2008Assignees: University of Sheffield, Biosynexus IncorporatedInventors: Simon Foster, James Mond, Simon Clarke, Philip McDowell, Kristy Brummel
-
Publication number: 20080095756Abstract: The present invention relates to compositions comprising lysostaphin variants and methods of using the same. In particular, the present invention provides de-immunized lysostaphin variants and methods of using the same (e.g., to treat microbial infection in or on a subject).Type: ApplicationFiled: September 5, 2007Publication date: April 24, 2008Applicant: Biosynexus IncorporatedInventors: Jeffrey Stinson, Luba Grinberg, James Mond
-
Publication number: 20080019976Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: ApplicationFiled: March 13, 2007Publication date: January 24, 2008Applicant: Biosynexus IncorporatedInventors: Jeffrey Stinson, Richard Schuman, James Mond, Andrew Lees, Gerald Fischer
-
Publication number: 20080014202Abstract: The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.Type: ApplicationFiled: December 19, 2006Publication date: January 17, 2008Applicant: Biosynexus IncorporatedInventors: Richard Schuman, John Kokai-Kun, Simon Foster, Jeffrey Stinson, Gerald Fischer